Weighing in: Emergent diabetes mellitus and second-generation antipsychotics
Date of Original Version
Of all the metabolic effects of some of the atypical second-generation antipsychotics, their potential to induce glucose dysregulation has induced a storm of controversy over the past several years. The numerous published epidemiologic studies are difficult to interpret due to the high background rate of type 2 diabetes mellitus in this population, the inherent problems with analysis of observational data, and the short duration of the available studies. A plan to monitor for weight gain, hypertriglyceridemia, glucose dysregulation, and other potential adverse metabolic effects resulting from antipsychotic treatment is critical.
Publication Title, e.g., Journal
Annals of Pharmacotherapy
Dufresne, Robert L.. "Weighing in: Emergent diabetes mellitus and second-generation antipsychotics." Annals of Pharmacotherapy 41, 10 (2007): 1725-1727. doi: 10.1345/aph.1K362.